NXN-188 was developed as a dual-action oral therapeutic for the acute treatment of migraine and cluster headaches. It was designed to address the underlying causes of migraine by combining two different mechanisms of action. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include Benzenebutanoic acid and 4-hydroxy-g-[4-hydroxy-3-(4-morpholinylmethyl)phenyl]-g-methyl-3-(4-morpholinylmethyl)-. Its PubChem CID is 242911.
Nxn-188
| CAS No | 6634-56-6 |
|---|---|
| Molecular Formula | C27H36N2O6 |
| Molecular Weight | 484.6 g/mol |
| Synonyms | 4,4-bis[4-hydroxy-3-(morpholin-4-ylmethyl)phenyl]pentanoic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
NXN-188 was developed as a dual-action oral therapeutic for the acute treatment of migraine and cluster headaches. It was designed to address the underlying causes of migraine by combining two different mechanisms of action.
The listed CAS number is 6634-56-6.
The listed molecular formula is C27H36N2O6.
The listed molecular weight is 484.6 g/mol.
4,4-bis[4-hydroxy-3-(morpholin-4-ylmethyl)phenyl]pentanoic acid.
The source lists Benzenebutanoic acid and 4-hydroxy-g-[4-hydroxy-3-(4-morpholinylmethyl)phenyl]-g-methyl-3-(4-morpholinylmethyl)-.